LungLife AI LungLB clinical validation study completion delayed

(Alliance News) - LungLife AI Inc on Thursday said it expects to conclude its clinical validation study for its LungLB test by the end of the fourth quarter of the year.

The California-based developer of clinical diagnostic solutions designed to address the early detection of lung cancer said the study was originally meant to be finalized by the end of September, but experienced delays in the provision of data from study sites.

LungLife's LungLB test is a blood-based tool used by clinicians to "make informed decisions about the management of lung nodules and lung cancer." The test is performed at the company's Thousand Oaks, California-based laboratory.

Back in June, LungLife published performance results for LungLB from a multi-site prospective study in patients with indeterminate pulmonary nodules.

The study was performed in collaboration with the MD Anderson Cancer Center in Houston, Texas, and the Icahn School of Medicine at Mount Sinai in New York. Its primary objective was to compare the LungLB test result with a lung biopsy diagnosis and assess performance in a patient cohort where commonly used nodule evaluation tools were not informative.

Shares in LungLife were down 8.1% at 85.00 pence each in London on Thursday morning.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.